Topics

Base Editing Drug Developer Beam Therapeutics Raises $135M in Series B Financing

10:15 EST 6 Mar 2019 | Genetic Engineering News

Beam Therapeutics, the company founded last year by CRISPR pioneer Feng Zhang, PhD, to develop treatments through base editing, said today it completed a $135 million Series B financing, bringing its total capital raised to $222 million in less than a year. Beam said it will use proceeds from the financing to advance its development […]

The post Base Editing Drug Developer Beam Therapeutics Raises $135M in Series B Financing appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Base Editing Drug Developer Beam Therapeutics Raises $135M in Series B Financing

NEXT ARTICLE

More From BioPortfolio on "Base Editing Drug Developer Beam Therapeutics Raises $135M in Series B Financing"

Quick Search